NS Healthcare is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
Home » whitepapers » Piramal Healthcare invests $2.5 million to further expand commercial ADC capacity

White Paper

Piramal Healthcare invests $2.5 million to further expand commercial ADC capacity

February 11, 2014

Piramal’s healthcare vertical has announced that it is to invest $2.5 million at its FDA-approved site in Grangemouth, UK, to upgrade one of its antibody drug conjugate (ADC) manufacturing suites from clinical phase to commercial grade in response to customer demand.

Download to find out more.

Download White Paper